NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-Lymphocyte Responses in Patients with Myelodysplastic Syndrome.

about

Immunological Approaches Towards Cancer and Inflammation: A Cross Talk.Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL-NKG2D Axis.Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies

P2860

Q52584421-CD5C0B71-3200-4249-B367-AE2AC8FACA25 Q55279130-8018E0E6-172E-4ED7-977B-A07554D898B5 Q57486479-C1830B99-678C-474C-AD62-E8AAE45172CF

P2860

NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-Lymphocyte Responses in Patients with Myelodysplastic Syndrome.

Item

http://www.wikidata.org/entity/Q47923445

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

NY-ESO-1 Vaccination in Combin ...... with Myelodysplastic Syndrome.

@en

NY-ESO-1 Vaccination in Combin ...... with Myelodysplastic Syndrome.

@nl

type

Item

label

NY-ESO-1 Vaccination in Combin ...... with Myelodysplastic Syndrome.

@en

NY-ESO-1 Vaccination in Combin ...... with Myelodysplastic Syndrome.

@nl

prefLabel

NY-ESO-1 Vaccination in Combin ...... with Myelodysplastic Syndrome.

@en

NY-ESO-1 Vaccination in Combin ...... with Myelodysplastic Syndrome.

@nl

P1476

NY-ESO-1 Vaccination in Combin ...... with Myelodysplastic Syndrome.

@en

P2093

Adam R Karpf

http://www.w3.org/2001/XMLSchema#string

Austin Miller

http://www.w3.org/2001/XMLSchema#string

Benjamin E Paluch

http://www.w3.org/2001/XMLSchema#string

Brandon L Martens

http://www.w3.org/2001/XMLSchema#string

Christopher S Hourigan

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Griffiths

http://www.w3.org/2001/XMLSchema#string

Eunice S Wang

http://www.w3.org/2001/XMLSchema#string

Gregory W Roloff

http://www.w3.org/2001/XMLSchema#string

Hong Yuen Wong

http://www.w3.org/2001/XMLSchema#string

Junko Matsuzaki

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses

Proposals for the classification of the myelodysplastic syndromes

International scoring system for evaluating prognosis in myelodysplastic syndromes

Flt3 permits survival during infection by rendering dendritic cells competent to activate NK cells

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy.

Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens.

NY-ESO-1: review of an immunogenic tumor antigen.

Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity

P31

scholarly article

P356

10.1158/1078-0432.CCR-17-1792

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Kunle Odunsi

P577

2017-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28947565

http://www.w3.org/2001/XMLSchema#string

P932

5844797

http://www.w3.org/2001/XMLSchema#string

NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-Lymphocyte Responses in Patients with Myelodysplastic Syndrome.

about

P2860

P2860

NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-Lymphocyte Responses in Patients with Myelodysplastic Syndrome.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P932